Safety and efficacy of peptide receptor radionuclide therapy with 177 Lu-DOTA 0-Tyr 3-octreotate in combination with amino acid solution infusion in Japanese patients with somatostatin receptor-positive, progressive neuroendocrine tumors

被引：0

作者：

Kobayashi, N. ^{[1
]}

Takano, S. ^{[2
]}

Ito, K. ^{[3
]}

Sugiura, M. ^{[2
]}

Ogawa, M. ^{[4
]}

Takeda, Y. ^{[1
]}

Okubo, N. ^{[1
]}

Suzuki, A. ^{[1
]}

Tokuhisa, M. ^{[1
]}

Kaneta, T. ^{[5
]}

Utsunomiya, D. ^{[3
]}

Hata, M. ^{[2
]}

Inoue, T. ^{[6
]}

Hosono, M. ^{[7
]}

Kinuya, S. ^{[8
]}

Ichikawa, Y. ^{[1
]}

机构：

[1] Yokohama City Univ, Dept Oncol, Grad Sch Med, Yokohama, Kanagawa, Japan

[2] Yokohama City Univ, Dept Radiat Oncol, Grad Sch Med, Yokohama, Kanagawa, Japan

[3] Yokohama City Univ, Dept Radiol, Grad Sch Med, Yokohama, Kanagawa, Japan

[4] Yokohama City Univ Med, Radiat Dept, Yokohama, Kanagawa, Japan

[5] Tohoku Univ, Grad Sch Med, Dept Diagnost Image Anal, Sendai, Miyagi, Japan

[6] Shonan Kamakura Gen Hosp, Adv Med Ctr, Kamakura, Kanagawa, Japan

[7] Kindai Univ, Dept Radiol, Fac Med, Osaka, Japan

[8] Japanese Soc Nucl Med, Tokyo, Japan

来源：

关键词：

peptide receptor radionuclide therapy; 177lu-dota0-tyr3-octreotate; neuroendocrine tumor;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

H16

引用

页码：149 / 149

页数：1